.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
US Department of Justice
Novartis
Covington
AstraZeneca
McKinsey
Federal Trade Commission
Deloitte
Moodys
Dow

Generated: September 21, 2017

DrugPatentWatch Database Preview

Teva Branded Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA BRANDED PHARM, and what generic alternatives to TEVA BRANDED PHARM drugs are available?

TEVA BRANDED PHARM has twenty-five approved drugs.

There are forty-six US patents protecting TEVA BRANDED PHARM drugs.

There are five hundred and seventy-seven patent family members on TEVA BRANDED PHARM drugs in thirty-seven countries.

Summary for Applicant: Teva Branded Pharm

Patents:46
Tradenames:24
Ingredients:14
NDAs:25
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-001Apr 3, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Teva Branded Pharm
VANTRELA ER
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL207975-001Jan 17, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
CENESTIN
estrogens, conjugated synthetic a
TABLET;ORAL020992-004Mar 13, 2000DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► Subscribe ► Subscribe
Teva Branded Pharm
NORDETTE-21
ethinyl estradiol; levonorgestrel
TABLET;ORAL-21018668-001May 10, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
PROAIR RESPICLICK
albuterol sulfate
POWDER, METERED;INHALATION205636-001Mar 31, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
QUARTETTE
ethinyl estradiol; levonorgestrel
TABLET;ORAL204061-001Mar 28, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
CENESTIN
estrogens, conjugated synthetic a
TABLET;ORAL020992-001Jun 21, 2002DISCNYesNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
VANTRELA ER
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL207975-005Jan 17, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Branded Pharm
AUSTEDO
deutetrabenazine
TABLET;ORAL208082-003Apr 3, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Branded Pharm

Paragraph IV activity for TEVA BRANDED PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
levonorgestrel; ethinyl estradiol;ethinyl estradiol
Tablets0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg
QUARTETTE
7/10/2013
levonorgestrel;ethinyl estradiol;ethinyl estradiol
Tablets0.1 mg/0.02 mg and 0.01 mg
LOSEASONIQUE
11/16/2009
conjugated estrogen (synthetic a)
Tablets0.3 mg, 0.45 mg and 0.9 mg
CENESTIN
3/19/2009
conjugated estrogen (synthetic a)
Tablets0.625 mg
CENESTIN
3/2/2009
conjugated estrogen (synthetic a)
Tablets1.25 mg
CENESTIN
11/3/2008
levonorgestrel; ethinyl estradiol; ethinyl estradiol
Tablets0.15 mg/0.03 mg/0.01 mg
SEASONIQUE
1/22/2008
levonorgestrel and ethinyl estradiol
Tablets0.15 mg/0.03 mg
SEASONALE
3/29/2004

Premature patent expirations for TEVA BRANDED PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva Branded Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,743,413 Suspension aerosol formulations► Subscribe
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method► Subscribe
7,749,989Estrogenic compounds, methods of using and methods of administering the same► Subscribe
9,108,010Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
7,772,219Methods of hormonal treatment utilizing extended cycle contraceptive regimens► Subscribe
7,459,445Estrogenic compounds and topical pharmaceutical formulations of the same► Subscribe
7,101,534Suspension aerosol formulations► Subscribe
9,533,111Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
9,737,674Dose counters for inhalers, inhalers and methods of assembly thereof► Subscribe
7,179,799(3) and (6) substituted estrogenic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Branded Pharm Drugs

Country Document Number Estimated Expiration
Denmark2692341► Subscribe
Cyprus1117140► Subscribe
Canada2532089► Subscribe
Japan4897570► Subscribe
Japan5888645► Subscribe
Japan2011256181► Subscribe
Japan2014128709► Subscribe
Japan5970037► Subscribe
European Patent Office1758631► Subscribe
Cyprus1115748► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Branded Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
0160011 00192Estonia► SubscribePRODUCT NAME: LEVONORGESTREEL JA ETUENUEUELOESTRADIOOL;REG NO/DATE: EE 894715 11.11.2015
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Covington
Cerilliant
McKesson
Argus Health
Deloitte
Accenture
Chubb
Daiichi Sankyo
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot